Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer. (PubMed, medRxiv) - Oct 9, 2026 - P2 | "We conducted a single-arm phase II trial ( NCT04361162 ) combining nivolumab, ipilimumab and radiation therapy to treat patients with pre-treated metastatic MSS PDAC (n=30). These findings suggest that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence. This may have implications for the design of future immunotherapy and vaccine strategies for PDAC."
Checkpoint inhibition • IO biomarker • Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • ACKR1 • CD8 • GZMK
|
|
Ana Lako; Anna L K Gonye; Aparna Parikh; Arnav Mehta; Benjamin L Schlechter; Beow Y Yeap; Brian M Wolpin; Christine Bolton; Colin D Weekes; Dana Pe'er; David P Ryan; David T Ting; Emily M Blaum; Hannah J Roberts; Irena Gushterova; Islam Baiev; James M Cleary; Jeffrey A Meyerhardt; Jeffrey W Clark; Jennifer Y Wo; Jill N Allen; Joseph D Mancias; Joseph W Franses; Julie L Koenig; Lawrence S Blaszkowsky; Leontios Pappas; Lorraine C Drapek; Lynn Bi; Marios Giannakis; Matthew B Yurgelun; Milan Parikh; Moshe Sade-Feldman; Nicole Carzo; Nir Hacohen; Olanike Asupoto; Ryan J Park; Sarah E Slater; Sarah Kang; Sofia Von Fedak; Steven M Corsello; Tarin M Grillo; Theodore S Hong; Thomas A Abrams; Thomas J Carmona-LaSalle
|